Injectable compositions for the postoperative treatment of malignant brain tumours
The use of nanoparticles loaded with chemotherapeutic agents in a composition for local postoperative treatment of brain tumors addresses the limitations of the blood-brain barrier, achieving enhanced chemotherapy efficacy by ensuring broader tumor coverage and prolonged drug release.
Patent Information
- Application Number
- PCT/RU2023/000412
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-12-07
- Filing Date
- 2023-12-28
- Publication Date
- 2025-06-12
AI Technical Summary
Current chemotherapy treatments for malignant brain tumors are limited by the blood-brain barrier (BBB), which restricts the penetration of chemotherapeutic agents to tumor cells, leading to incomplete treatment and resistance.
A pharmaceutical composition based on nanoparticles, made from a copolymer of L-glutamic acid or L-aspartic acid and phenylalanine, loaded with chemotherapeutic agents like doxorubicin, is developed. This composition is designed for local postoperative treatment of brain tumors, allowing for gradual release of the drug and distribution with cerebrospinal fluid, thereby overcoming the limitations of the BBB.
The nanoparticle-based composition achieves a higher volume of tumor perifocal zone coverage, enhancing the effectiveness of chemotherapy by prolonging the drug's presence in the target area and reducing resistance, while minimizing inflammatory responses.